Harbour Investments’s Axsome Therapeutics AXSM Stock Holding History

Harbour Investments’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$14.7K	Hold	60	–	–	﹤0.01%	3135
2026 Q1	$10.1K	Hold	60	–	–	﹤0.01%	3256
2025 Q4	$11K	Hold	60	–	–	﹤0.01%	2697
2025 Q3	$7.29K	Hold	60	–	–	﹤0.01%	2823
2025 Q2	$6.26K	Hold	60	–	–	﹤0.01%	2785
2025 Q1	$7K	Buy	60 +36	+150%	+$4.1K	﹤0.01%	2685
2024 Q4	$2.03K	Buy	+24	New	+$2.21K	﹤0.01%	3017
2023 Q4	–	Sell	-65	Closed	-$4.54K	–	3131
2023 Q3	$4.54K	Sell	65 -300	-82%	-$22.4K	﹤0.01%	2304
2023 Q2	$26.2K	Buy	365 +300	+462%	+$22.1K	﹤0.01%	1649
2023 Q1	$4.01K	Hold	65	–	–	﹤0.01%	2354
2022 Q4	$5.01K	Buy	+65	New	+$3.88K	﹤0.01%	2216
2021 Q4	–	Sell	-2	Closed	–	–	2694
2021 Q3	$0	Hold	2	–	–	﹤0.01%	3723
2021 Q2	$0	Hold	2	–	–	﹤0.01%	3758
2021 Q1	$0	Buy	+2	New	+$141	﹤0.01%	3591

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Harbour Investments's AXSM Position: Q2 2026 in Review

Harbour Investments held its Axsome Therapeutics (AXSM) position steady in Q2 2026 at 60 shares worth $14.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3135.

Harbour Investments first reported a position in AXSM in Q1 2021 and has held it in 14 quarters since. The position peaked at $26.2K in Q2 2023. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Harbour Investments held 60 shares of Axsome Therapeutics worth $14.7K as of Q2 2026.
Harbour Investments left its Axsome Therapeutics share count unchanged in Q2 2026.
Axsome Therapeutics made up ﹤0.01% of Harbour Investments's portfolio in Q2 2026, its #3135 holding.
Harbour Investments first reported a position in Axsome Therapeutics in Q1 2021 and has held it in 14 quarters since.
Harbour Investments's Axsome Therapeutics position peaked at $26.2K in Q2 2023.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Harbour Investments's 13F filing for Q2 2026, filed 12 Aug 2026.